CD274 and non-small cell lung carcinoma: According to the CheckMate 9LA trial report, the combination of nivolumab plus ipilimumab with chemotherapy demonstrated longer progression-free survival (PFS) and overall survival (OS) compared to traditional platinum-based therapy in patients with NSCLC, regardless of their PD-L1 expression levels [14].